Bayer IR Newsfeed: Events
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. 
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.
This page shows you the latest items in this publication.
221 records returned
19.11.09: Positive Results from Chronic Study with Bayer's Rivaroxaban Will be Presented As a Late Breaker at ASH 2009
Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Positive Results from Chronic Study with Bayer's Rivaroxaban Will be Presented As a Late Breaker at ASH 2009Endpoints met in EINSTEIN-Extension Trial in the Secondary Prevention of Recurrent Symptomatic VTEmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 20, 2009 Category: Pharmaceuticals Source Type: news
11.11.09: Bayer's Perspective on Sustainability 2009, LeverkusenEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer's Perspective on Sustainability 2009, LeverkusenAll press conferences (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 4, 2009 Category: Pharmaceuticals Source Type: news
02.11.09: Successful purchase of trait platform with extensive product pipeline:Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer CropScience completes acquisition of biotech company Athenix Corp.Purchase price of USD 365 million plus milestonesmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 2, 2009 Category: Pharmaceuticals Source Type: news
27.10.09: Renewed year-on-year growth in underlying EBITDA in the third quarter of 2009:Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer back on the uptrend HealthCare again strong - weak quarter at CropScience - MaterialScience substantially improved / Group sales EUR 7,392 million (minus 7.0 percent) / EBITDA before special items EUR 1,499 million (plus 0.4 percent) / Net income EUR 249 million (minus 10.1 percent) / Net cash flow EUR 1,517 million (plus 22.9 percent) / Full-year Group forecast confirmedmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 27, 2009 Category: Pharmaceuticals Source Type: news
23.10.09: Bayer and Onyx Initiate Phase III Trial of Nexavar® in Patients with Non-Responsive Thyroid CancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Patients with Non-Responsive Thyroid Cancermehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 23, 2009 Category: Pharmaceuticals Source Type: news
22.10.09: Swiss regulatory authority Swissmedic announces results of its analysis of current studies on the risks of hormonal contraceptives:Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The risk of venous thromboembolism for drospirenone containing oral contraceptives is comparable to the risk of other oral contraceptives available on the marketmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 22, 2009 Category: Pharmaceuticals Source Type: news
27.10.09: News Conference Call and Report for the Third Quarter of 2009Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
News Conference Call and Report for the Third Quarter of 2009Financial Report as of September 30, 2009All press conferences (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 20, 2009 Category: Pharmaceuticals Source Type: news
27.10.09: Q3 2009 Investor Conference CallEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Q3 2009 Investor Conference CallFinancial Report as of September 30, 2009All investor conferences (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 20, 2009 Category: Pharmaceuticals Source Type: news
09.10.09: Improvement in ordersEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer MaterialScience AG ends reduced working hours at German sitesRates of pay to be raised again / Solidarity-based solution has proved its worth / Opening clause in collective agreement applied from February to the end of October 2009mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 10, 2009 Category: Pharmaceuticals Source Type: news
05.10.09: Phase-III data presented at the World Congress of Gynecology & Obstetrics (FIGO):Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer's novel oral contraceptive Qlaira® significantly reduces heavy menstrual bleedingResults also confirm significant improvement in blood iron levelsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 5, 2009 Category: Pharmaceuticals Source Type: news
30.09.09: Results Reported for Exploratory Phase II Trial of Nexavar in Combination with Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast CancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Results Reported for Exploratory Phase II Trial of Nexavar in Combination with Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast CancerPreliminary results require further analysis and interpretationmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 30, 2009 Category: Pharmaceuticals Source Type: news
23.09.09: Phase II Study in Advanced Breast Cancer:Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Nexavar® in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free SurvivalFirst presentation of results at joint ECCO-ESMO congress in Berlin, Germanymehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 23, 2009 Category: Pharmaceuticals Source Type: news
22.09.09: Results of a Phase II study in Renal Cell Carcinoma (RCC):Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer PatientsPresentation of complete results at joint 15th ECCO and 34th ESMO Multidisciplinary Congress / Confirmation of topline data presented at ASCO 2009mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 22, 2009 Category: Pharmaceuticals Source Type: news
17.09.09: Greater focus on future technologies:Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer CropScience accelerates expansion of biotech and seed business with investments of around EUR 3.5 billion through 2018BioScience sales of EUR 1.4 billion targeted for 2018 / Biotech licensing agreements tap into business potential in excess of EUR 500 million / Peak sales potential of new crop protection actives raised to EUR 1.25 billionmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 17, 2009 Category: Pharmaceuticals Source Type: news
17.09.09: Joint 15th ECCO and 34th ESMO Multidisciplinary Congress:Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009Marketed Products and Pipeline Compounds Highlighted at Presentation Sessionsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 17, 2009 Category: Pharmaceuticals Source Type: news
15.09.09: Bayer Supervisory Board decides company's future management line-up:Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Dr. Marijn E. Dekkers to be new CEO of Bayer from October 1, 2010Werner Wenning extends his contract by eight months / CFO Klaus Kühn to retire on April 30, 2010 / Werner Baumann to be new CFO / BHC CEO Arthur J. Higgins to leave Bayer at his own requestmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 15, 2009 Category: Pharmaceuticals Source Type: news
03.09.09: Bayer and Algeta Enter Global Agreement for Development and Commercialization of Treatment for Bone Metastases in Cancer PatientsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer and Algeta Enter Global Agreement for Development and Commercialization of Treatment for Bone Metastases in Cancer PatientsPhase III compound represents potential therapy for life-threatening conditionmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 3, 2009 Category: Pharmaceuticals Source Type: news
02.09.09: Bayer Acquires Two Prescription Dermatology Product Lines from SkinMedica in the U.S.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer Acquires Two Prescription Dermatology Product Lines from SkinMedica in the U.S.Bayer subsidiary Intendis expands presence in the U.S. / Asset purchase agreement signed for marketed prescription products Desonate® and NeoBenz® Micromehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 2, 2009 Category: Pharmaceuticals Source Type: news
30.08.09: Bayer Committed to Prevention of Arterial Thrombosis:Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer Completes Enrollment into Major Phase III Study with Rivaroxaban (ROCKET AF)ROCKET AF study compares rivaroxaban to warfarin in the prevention of stroke and non-CNS systemic embolism in patients with Atrial Fibrillation / Bayer Schering Pharma supports Thrombosis Research Institute's launch of GARFIELD - a global patient Registry to evaluate 'real life' outcomes in the prevention of stroke in patients with Atrial Fibrillation / Fast Track designation for rivaroxaban development program in the secondary prevention of cardiovascular events in patients with Acute Coronary Syndrome recognizes high unmet medical need.mehr...
Source: Bayer IR Newsfeed: Events - August 31, 2009 Category: Pharmaceuticals Source Type: news
19.08.09: Trait platform with extensive product pipeline to deliver innovative solutions for farmers:Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer CropScience acquires US biotech company Athenix Corp.mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 20, 2009 Category: Pharmaceuticals Source Type: news
19.08.09: New Levitra® formulation submitted for registration in the EUEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
New Levitra® formulation submitted for registration in the EUFirst orodispersible tablet for the treatment of erectile dysfunctionmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 19, 2009 Category: Pharmaceuticals Source Type: news
29.07.09: Interim report for the second quarter of 2009:Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer robust in a difficult environmentHealthCare strong - further growth at CropScience - MaterialScience stabilized / Group sales EUR 8,009 million (minus 5.9 percent) / EBITDA before special items EUR 1,765 million (minus 6.9 percent) / EBIT before special items EUR 1,101 million (minus 11.8 percent) / Group net income EUR 532 million (minus 7.3 percent) / Net cash flow EUR 1,399 million (plus 57.4 percent) / Earnings targets for full year 2009 confirmedmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 29, 2009 Category: Pharmaceuticals Source Type: news
26.02.10: 2009 Annual ReportEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
2009 Annual ReportAll investor conferences (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 29, 2009 Category: Pharmaceuticals Source Type: news
22.07.09: Nexavar® in Combination with Chemotherapy Shown To Extend Progression-Free Survival in Patients with Advanced Breast CancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Nexavar® in Combination with Chemotherapy Shown To Extend Progression-Free Survival in Patients with Advanced Breast CancerStatistically Significant Results Reported from a Phase II Study Combining Two Oral Cancer Therapiesmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 23, 2009 Category: Pharmaceuticals Source Type: news
21.07.09: Long-term cooperation with leading Australian research institute CSIRO:Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer CropScience expands global R&D activities in seeds and traits by setting up new research focus area in cerealsSuperior solutions for wheat farmers could be available as early as 2015 mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 21, 2009 Category: Pharmaceuticals Source Type: news
16.07.09: Bayer MaterialScience lifts force majeure for TDI in EuropeEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer MaterialScience lifts force majeure for TDI in Europemehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 16, 2009 Category: Pharmaceuticals Source Type: news
14.07.09: New Drug Application for Rivaroxaban in the U.S.:Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Update on Status of Rivaroxaban Complete Response Letter From U.S. FDAmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 15, 2009 Category: Pharmaceuticals Source Type: news
13.07.09: International Conference on Alzheimer's Disease (ICAD):Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer presents positive Phase II data with florbetabenPotential to visualize beta-Amyloid plaques in Patients with Alzheimer's disease demonstrated / Florbetaben may innovate the diagnostic capabilitiesmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 13, 2009 Category: Pharmaceuticals Source Type: news
09.07.09: Expansion of diabetes portfolio in growth market China:Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer acquires exclusive rights to Bioton's insulin SciLin® mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 9, 2009 Category: Pharmaceuticals Source Type: news
08.07.09: Bayer submits first-in-class estradiol-based oral contraceptive for approval in the U.S.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer submits first-in-class estradiol-based oral contraceptive for approval in the U.S.FDA approval requested for oral contraception and treatment of heavy and/or prolonged menstrual bleedingmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 8, 2009 Category: Pharmaceuticals Source Type: news
07.07.09: Bayer MaterialScience declares force majeure for TDI in EuropeEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer MaterialScience declares force majeure for TDI in Europemehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 7, 2009 Category: Pharmaceuticals Source Type: news
01.07.09: Bayer files patent infringement lawsuit against TevaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer files patent infringement lawsuit against Tevamehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 5, 2009 Category: Pharmaceuticals Source Type: news
29.06.09: Bayer CropScience and Monsanto sign cross licensing agreement on herbicide tolerance traits in rapeseed/canolaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer CropScience and Monsanto sign cross licensing agreement on herbicide tolerance traits in rapeseed/canola mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 29, 2009 Category: Pharmaceuticals Source Type: news
25.06.09: New choices for corn and soybean farmers worldwide:Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer CropScience and DuPont expand collaboration with broad license agreementsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 25, 2009 Category: Pharmaceuticals Source Type: news
26.02.10: Financial News ConferenceEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Financial News ConferenceAll press conferences (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 25, 2009 Category: Pharmaceuticals Source Type: news
29.04.10: Q1 2010 Interim ReportEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Q1 2010 Interim ReportAll investor conferences (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 25, 2009 Category: Pharmaceuticals Source Type: news
28.10.10: Q3 2010 Interim ReportEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Q3 2010 Interim ReportAll investor conferences (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 25, 2009 Category: Pharmaceuticals Source Type: news
02.06.09: Bayer HealthCare and Genzyme Finalize Strategic Alliance AgreementEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer HealthCare and Genzyme Finalize Strategic Alliance Agreementmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 3, 2009 Category: Pharmaceuticals Source Type: news
01.06.09: Bayer and Onyx Initiate Phase III Trial of Nexavar® in Non-small Cell Lung CancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Non-small Cell Lung Cancermehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 1, 2009 Category: Pharmaceuticals Source Type: news
30.05.09: 45th American Society of Clinical Oncology Annual Meeting (ASCO):Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer Schering Pharma Announces New Data on Novel Anti-cancer Compound BAY 73-4506mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 30, 2009 Category: Pharmaceuticals Source Type: news
28.05.09: Venous Blood Clot Prevention after Hip or Knee Replacement Surgery:Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
U.S. FDA Issues Complete Response Letter for Rivaroxaban No new clinical or non-clinical studies to be conducted as a pre-requisite for approvalmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 28, 2009 Category: Pharmaceuticals Source Type: news
28.05.09: Phase III Trial Started to Evaluate Combination Therapy of Nexavar® and Tarceva® in Patients with Liver CancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Phase III Trial Started to Evaluate Combination Therapy of Nexavar® and Tarceva® in Patients with Liver Cancermehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 28, 2009 Category: Pharmaceuticals Source Type: news
22.05.09: Milestone for the cotton-pipelineEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
U.S. Department of Agriculture grants approval for Bayer CropScience's GlyTolmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 23, 2009 Category: Pharmaceuticals Source Type: news
20.05.09: Nexavar® Approved in Japan for the Treatment of Advanced Liver CancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Nexavar® Approved in Japan for the Treatment of Advanced Liver Cancermehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 20, 2009 Category: Pharmaceuticals Source Type: news
19.05.09: American Thoracic Society (ATS) congress, San Diego, USA:Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer Schering Pharma presents positive results of phase II study with Riociguatmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 19, 2009 Category: Pharmaceuticals Source Type: news
03.05.10: Payment of Dividend for Fiscal 2009Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Payment of Dividend for Fiscal 2009All stockholder's meetings (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 19, 2009 Category: Pharmaceuticals Source Type: news
29.07.10: Q2 2010 Interim ReportEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Q2 2010 Interim ReportAll investor conferences (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 19, 2009 Category: Pharmaceuticals Source Type: news
15.05.09: Bayer and Onyx Announce Nexavar® Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual MeetingEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer and Onyx Announce Nexavar® Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meetingmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 15, 2009 Category: Pharmaceuticals Source Type: news
14.05.09: Qlaira® - innovative estradiol-based oral contraceptive available in Europe from May onwardsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Qlaira® - innovative estradiol-based oral contraceptive available in Europe from May onwardsA new oral contraceptive delivering the same estrogen as produced by the female bodymehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 14, 2009 Category: Pharmaceuticals Source Type: news
05.05.09: Bayer Schering Pharma is starting Phase III studies with an innovative low-dose contraceptive patchEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer Schering Pharma is starting Phase III studies with an innovative low-dose contraceptive patchmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 7, 2009 Category: Pharmaceuticals Source Type: news
